Related Experiment Video
Updated: Nov 25, 2025

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant
Liang Gao1, Kunwei Shen2, Ni Yin3
1Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.
Background:
Tamoxifen and fulvestrant, both approved for endocrine therapy, have remarkably increased the prognosis of hormone receptor-positive breast cancer patients. However, acquired resistance to endocrine therapy greatly reduces its clinical efficacy. Accumulating evidence suggests a pivotal role of non-coding RNAs (ncRNAs) in breast cancer endocrine resistance, but the specific functions of ncRNAs in tamoxifen and fulvestrant resistance remain largely unknown.
Methods:
Microarray analysis was performed for endocrine therapy sensitive (MCF-7), tamoxifen-resistant (LCC2), and dual tamoxifen and fulvestrant-resistant (LCC9) breast cancer cells. Gene ontology and pathway analysis were conducted for functional prediction of the unannotated differentially expressed ncRNAs. Competing endogenous RNA regulatory networks were constructed.
Results:
We discovered a total of 3,129 long non-coding RNAs (lncRNAs), 13,556 circular RNAs (circRNAs), 132 microRNAs, and 3358 mRNAs that were significantly differentially expressed. We constructed co-expression networks for lncRNA-mRNA, circRNA-mRNA, and microRNA-mRNA. In addition, we established lncRNA-microRNA-mRNA and circRNA-microRNA-mRNA regulatory networks to depict ncRNA crosstalk and transcriptomic regulation of endocrine resistance.
Conclusions:
Our study delineates a comprehensive profiling of ncRNAs in tamoxifen and fulvestrant resistant breast cancer cells, which enriches our understanding of endocrine resistance and sheds new light on identifying novel endocrine resistance biomarkers and potential therapeutic targets to overcome endocrine resistance.
Insights
This study profiles non-coding RNAs (ncRNAs) in endocrine-resistant breast cancer cells, revealing their role in tamoxifen and fulvestrant resistance. Findings offer new biomarkers and therapeutic targets for overcoming resistance.
Area of Science:
- Genomics
- Molecular Biology
- Oncology
Background:
- Hormone receptor-positive breast cancer treatment relies on tamoxifen and fulvestrant.
- Acquired resistance to endocrine therapy limits treatment efficacy.
- Non-coding RNAs (ncRNAs) are implicated in endocrine resistance, but their specific roles are unclear.
Purpose of the Study:
- To comprehensively profile ncRNAs in tamoxifen- and fulvestrant-resistant breast cancer cells.
- To investigate the role of ncRNAs in acquired endocrine resistance.
- To identify potential biomarkers and therapeutic targets for overcoming endocrine resistance.
Main Methods:
- Microarray analysis of endocrine-sensitive and resistant breast cancer cell lines (MCF-7, LCC2, LCC9).
- Gene ontology and pathway analysis for functional prediction of differentially expressed ncRNAs.
- Construction of competing endogenous RNA (ceRNA) regulatory networks (lncRNA-mRNA, circRNA-mRNA, microRNA-mRNA, and integrated networks).
Main Results:
- Identified significant differential expression of 3,129 long non-coding RNAs (lncRNAs), 13,556 circular RNAs (circRNAs), 132 microRNAs, and 3,358 messenger RNAs (mRNAs).
- Constructed co-expression and regulatory networks (lncRNA-microRNA-mRNA, circRNA-microRNA-mRNA) to illustrate ncRNA crosstalk and transcriptomic regulation.
- Detailed ncRNA profiles in endocrine-resistant cells were established.
Conclusions:
- Provides a comprehensive ncRNA profile in tamoxifen- and fulvestrant-resistant breast cancer.
- Enhances understanding of the mechanisms underlying endocrine resistance.
- Highlights potential novel biomarkers and therapeutic strategies to combat endocrine resistance in breast cancer.
Related Concept Videos
MicroRNAs
MicroRNAs
lncRNA - Long Non-coding RNAs
The Nucleolus

